Solvay Pharmaceuticals Announces Strategic Partnership With HUYA to Access new Drug Candidates ...(nd CEO of HUYA This partnership with S...)

About Solvay Pharmaceuticals

Solvay Pharmaceuticals is a research driven group of companies that constitutes the global pharmaceutical business of the Solvay Group. The companies seek to fulfil carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardiometabolic, influenza vaccines, gastroenterology and men's and women's health. Its 2008 sales were EUR 2.7 billion and it employs more than 9,000 people worldwide. For more information, visit www.solvaypharmaceuticals.com.

About HUYA Bioscience International

HUYA Bioscience International is a leader in enabling and accelerating the global codevelopment of novel biopharmaceutical product opportunities originating in China. HUYA has established extensive collaborations with Chinese biopharmaceutical academic and commercial organizations to speed development and value creation in world-wide markets for China-sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner-of-choice for building and maximizing the value of biopharmaceutical innovation in China. HUYA is jointly headquartered in San Diego, CA, and Shanghai, PRC. Additional information about the company is available at www.huyabio.com.

    For more information, please contact:

    Media contacts HUYA Bioscience International:
    Juliet Travis
    (510) 452-3771

'/>"/>
SOURCE  Solvay Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 
Related biology technology :

1. Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
2. 40 High-Achieving Students with Cystic Fibrosis Receive $100,000 Total in Higher Education Scholarships From SolvayCARES(SM)
3. Stallergenes Signs an Exclusive Partnership Agreement With Solvay Pharmaceuticals for the Promotion and Distribution of its Products in Russia and the CIS*
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences